Meeting
2024 ASCO Annual Meeting
Unveiling consistency: A large-scale analysis of conference proceedings and subsequent publications in oncology clinical trials using large language models.
Authors
Kyeryoung Lee
IMO Health, Rosemont, IL
Kyeryoung Lee , Hunki Paek , Liang-Chin Huang , Surabhi Datta , Augustine Annan , Nneka Ofoegbu , Mitchell K Higashi , C. Beau Hilton , Sam Rubinstein , Andrew Cowan , Mary Kwok , Jeremy Lyle Warner , Hua Xu , Xiaoyan Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 7568)
DOI
10.1200/JCO.2024.42.16_suppl.7568
Abstract #
7568
Poster Bd #
205
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.
First Author: Dagmar Hess
Poster
2023 ASCO Annual Meeting
A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9.
First Author: Saad Zafar Usmani
Poster
2022 ASCO Annual Meeting
Safety and efficacy of daratumumab use in patients with renal impairment and hemodialysis.
First Author: Mateusz Niewinski
Poster
2021 ASCO Annual Meeting
Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.
First Author: Xavier Leleu